AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
AstraZeneca initiates Phase III clinical programme evaluating NKTR-118 for treatment of opioid-induced constipation.
AstraZeneca announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC). The Phase III clinical programme is designed to investigate the safety and efficacy of NKTR-118 as a medicine to relieve opioid induced constipation, a common side effect of prescription opioids when used for chronic pain management. NKTR-118 is part of the exclusive worldwide licence agreement announced on 21 Sep 2009, between AstraZeneca and Nektar Therapeutics (Nektar). The Phase III clinical programme will consist of two 12-week, randomized, placebo-controlled …
-
- ISTA starts Phase III clinical programme for REMURA in dry eye disease.
-
News wire article from: Europe Intelligence Wire
September 16, 2010
700+ words
-
- Helsinn Therapeutics enrolls patients in Phase III clinical programme of...
-
News wire article from: Europe Intelligence Wire
August 23, 2011
700+ words
-
- Santarus begins enrolment in Phase III clinical programme for Rifamycin SV...
-
News wire article from: Chemical Business Newsbase
June 2, 2010
700+ words
-
- Shionogi-ViiV Healthcare LLC initiates Phase III clinical programme for...
-
News wire article from: Chemical Business Newsbase
October 21, 2010
700+ words
-
- AstraZeneca initiates phase III clinical programme evaluating NKTR-118 for...
-
News wire article from: Chemical Business Newsbase
March 15, 2011
700+ words
